Cocrystal Pharma (8CC) Stock Price & Analysis
8CC Stock Chart & Stats
- Day’s Range
- EUR 0.84 - EUR 0.84
- 52-Week Range
- EUR 0.69 - EUR 1.30
- Previous Close
- EUR 0.87
- Volume
- N/A
- Average Volume (3M)
- 6
- Market Cap
- EUR 17.16M
- Enterprise Value
- EUR 13.57M
- Total Cash (Recent Filing)
- EUR 2.17M
- Total Debt (Recent Filing)
- EUR 1.34M
- Price to Earnings (P/E)
- ―
- Beta
- 0.87
- Next Earnings
- Nov 16, 2026 (Est.)
- EPS Estimate
- -0.16
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Clinical Progress
Completing dosing advances CDI-988 from early clinical testing toward efficacy data, an important development milestone for the lead program. If results support the candidate, the study could improve partnering and commercialization prospects, although efficacy remains unproven.
Antiviral Platform
A structure-based discovery approach applied across multiple viral diseases gives Cocrystal a platform-oriented development model rather than reliance on one research idea. A broader pipeline can create several opportunities for clinical validation, licensing, or future commercialization.
Funding Support
The $5 million financing strengthens near-term capital resources while the company advances its clinical programs. Continued backing from a longstanding investor may also support strategic credibility, giving Cocrystal greater capacity to fund development before potential clinical or partnership milestones.
Bears Say
Persistent Unprofitability
Revenue remains far too small to support the current research and operating structure, leaving Cocrystal deeply unprofitable. Until a candidate generates meaningful commercial or partnered revenue, ongoing losses will continue to consume resources and make financial performance dependent on external funding.
Cash Burn
Negative operating and free cash flow show that reported losses are translating into substantial cash outflows rather than mainly non-cash charges. Even with burn improving from 2024, the company lacks scalable operating inflows, so continued development will require disciplined spending or additional financing.
Weakened Balance Sheet
Higher leverage combined with a sharply smaller asset base leaves a thinner financial buffer for a clinical-stage company. The reduced equity cushion increases sensitivity to continued losses and may constrain flexibility in funding trials, negotiating partnerships, or absorbing development setbacks.
8CC FAQ
What was Cocrystal Pharma’s price range in the past 12 months?
What is Cocrystal Pharma’s market cap?
When is Cocrystal Pharma’s upcoming earnings report date?
How were Cocrystal Pharma’s earnings last quarter?
Is Cocrystal Pharma overvalued?
Does Cocrystal Pharma pay dividends?
What is Cocrystal Pharma’s EPS estimate?
How many shares outstanding does Cocrystal Pharma have?
What happened to Cocrystal Pharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cocrystal Pharma?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Cocrystal Pharma
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James E. Sapirstein
- Employees
- 10
- Website
- www.cocrystalpharma.com
- Address
- 19805 North Creek Parkway, Bothell, WA, 98011, US
Cocrystal Pharma (8CC) Earnings & Revenues
8CC Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 5 | 13 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 1 | 0 | 11 |
